{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:24:00Z","timestamp":1791390240235,"version":"4.3.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10072-026-09000-9","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:34:05Z","timestamp":1775090045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful treatment with efgartigimod as rescue therapy in acute attack of MOGAD: a case report"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-3546","authenticated-orcid":false,"given":"Yi-Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Qiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Lei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"9000_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/s1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, J Palace (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 22:268\u2013282. https:\/\/doi.org\/10.1016\/s1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"9000_CR2","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1007\/s00415-023-11737-8","volume":"270","author":"A Al-Ani","year":"2023","unstructured":"Al-Ani A, Chen JJ, Costello F (2023) Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges. J Neurol 270:4132\u20134150. https:\/\/doi.org\/10.1007\/s00415-023-11737-8","journal-title":"J Neurol"},{"key":"9000_CR3","doi-asserted-by":"publisher","first-page":"103693","DOI":"10.1016\/j.autrev.2024.103693","volume":"24","author":"BP Trewin","year":"2025","unstructured":"Trewin BP, Brilot F, Reddel SW, Dale RC, Ramanathan S (2025) MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmun Rev 24:103693. https:\/\/doi.org\/10.1016\/j.autrev.2024.103693","journal-title":"Autoimmun Rev"},{"key":"9000_CR4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/s1474-4422(21)00218-0","volume":"20","author":"R Marignier","year":"2021","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A, Pr\u00f6bstel AK, Aktas O, Alexopoulos H, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, S\u00e8ze JD, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selmaj K, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, B Hemmer (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20:762\u2013772. https:\/\/doi.org\/10.1016\/s1474-4422(21)00218-0","journal-title":"Lancet Neurol"},{"key":"9000_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/acn3.51759","volume":"10","author":"JD Santoro","year":"2023","unstructured":"Santoro JD, Beukelman T, Hemingway C, Hokkanen SRK, Tennigkeit F, Chitnis T (2023) Attack phenotypes and disease course in pediatric MOGAD. Ann Clin Transl Neurol 10:672\u2013685. https:\/\/doi.org\/10.1002\/acn3.51759","journal-title":"Ann Clin Transl Neurol"},{"key":"9000_CR6","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Z Xiao (2018) Adverse Effects of Immunoglobulin Therapy. Front Immunol 9:1299. https:\/\/doi.org\/10.3389\/fimmu.2018.01299","journal-title":"Front Immunol"},{"key":"9000_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA (2022) Efgartigimod: First Approval. Drugs 82:341\u2013348. https:\/\/doi.org\/10.1007\/s40265-022-01678-3","journal-title":"Drugs"},{"key":"9000_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr., Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, R Mantegazza (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"9000_CR9","doi-asserted-by":"publisher","first-page":"e30421","DOI":"10.1016\/j.heliyon.2024.e30421","volume":"10","author":"Z Li","year":"2024","unstructured":"Li Z, Xu Q, Huang J, Zhu Q, Yang X, Zhang M, Zhang S, Huang S, Yu G, Zheng P, Qin X, Feng J (2024) Efgartigimod as rescue treatment in acute phase of neuromyelitis optica spectrum disorder: A Case Report. Heliyon 10:e30421. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30421","journal-title":"Heliyon"},{"key":"9000_CR10","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1007\/s00415-024-12556-1","volume":"271","author":"F Zhu","year":"2024","unstructured":"Zhu F, Wang WF, Ma CH, Liang H, Jiang YQ (2024) Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod. J Neurol 271:5911\u20135915. https:\/\/doi.org\/10.1007\/s00415-024-12556-1","journal-title":"J Neurol"},{"key":"9000_CR11","doi-asserted-by":"publisher","first-page":"1624660","DOI":"10.3389\/fimmu.2025.1624660","volume":"16","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Zhang J, Li H, Wei L, Tian Y, Wang K (2025) Case Report: Efgartigimod as an additional therapy for MOG antibody-associated disease overlapping GFAP-IgG. Front Immunol 16:1624660. https:\/\/doi.org\/10.3389\/fimmu.2025.1624660","journal-title":"Front Immunol"},{"key":"9000_CR12","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1212\/WNL.0000000000211721","volume":"104","author":"J Du","year":"2025","unstructured":"Du J, Cao S, Cao L, Tian Y, Qi X (2025) A Case Report of Efgartigimod in the Treatment of Recurrent Severe Anti-NMDAR Encephalitis Complicated with MOGAD (P10-8.016). Neurology 104:4509. https:\/\/doi.org\/10.1212\/WNL.0000000000211721","journal-title":"Neurology"},{"key":"9000_CR13","doi-asserted-by":"publisher","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","volume":"13","author":"E Sechi","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, Lopez-Chiriboga AS, Pittock SJ, EP Flanagan (2022) Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol 13:885218. https:\/\/doi.org\/10.3389\/fneur.2022.885218","journal-title":"Front Neurol"},{"key":"9000_CR14","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1007\/s10072-024-07678-3","volume":"45","author":"SQ Huang","year":"2024","unstructured":"Huang SQ, Yuan ZH, Hong Y, Jiang T, Zhao HD, Shi JQ (2024) Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report. Neurol Sci 45:5511\u20135515. https:\/\/doi.org\/10.1007\/s10072-024-07678-3","journal-title":"Neurol Sci"},{"key":"9000_CR15","doi-asserted-by":"publisher","unstructured":"Shimizu F, M Nakamori (2024) Blood-Brain Barrier Disruption in Neuroimmunological Disease. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms251910625","DOI":"10.3390\/ijms251910625"},{"key":"9000_CR16","doi-asserted-by":"publisher","unstructured":"Tanaka K, Kezuka T, Ishikawa H, Tanaka M, Sakimura K, Abe M, Kawamura M (2023) Pathogenesis, Clinical Features, and Treatment of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Autoantibody-Associated Disorders Focusing on Optic Neuritis with Consideration of Autoantibody-Binding Sites: A Review. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms241713368","DOI":"10.3390\/ijms241713368"},{"key":"9000_CR17","doi-asserted-by":"publisher","first-page":"105941","DOI":"10.1016\/j.msard.2024.105941","volume":"92","author":"N Kosior","year":"2024","unstructured":"Kosior N, Perrier RL, Casserly C, Morrow SA, Racosta JM (2024) New insights into the use of high dose corticosteroids and plasmapheresis in persons with MOGAD and NMOSD. Mult Scler Relat Disord 92:105941. https:\/\/doi.org\/10.1016\/j.msard.2024.105941","journal-title":"Mult Scler Relat Disord"},{"key":"9000_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","volume":"252","author":"JJ Chen","year":"2023","unstructured":"Chen JJ, Flanagan EP, Pittock SJ, Stern NC, Tisavipat N, Bhatti MT, Chodnicki KD, Tajfirouz DA, Jamali S, Kunchok A, Eggenberger ER, Nome MAD, Sotirchos ES, Vasileiou ES, Henderson AD, Arnold AC, Bonelli L, Moss HE, Navarro SEV, Padungkiatsagul T, Stiebel-Kalish H, Lotan I, Wilf-Yarkoni A, Danesh-Meyer H, Ivanov S, Huda S, Forcadela M, Hodge D, Poullin P, Rode J, Papeix C, Saheb S, Vignal C, Hacohen Y, Pique J, Maillart E, Deschamps R, Audoin B, R Marignier (2023) Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks. Am J Ophthalmol 252:213\u2013224\u00a0M Boudot de la Motte. https:\/\/doi.org\/10.1016\/j.ajo.2023.02.013","journal-title":"Am J Ophthalmol"},{"key":"9000_CR19","doi-asserted-by":"publisher","first-page":"953993","DOI":"10.3389\/fimmu.2022.953993","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Kong L, Zhao Z, Shi Z, Chen H, Lang Y, Lin X, Du Q, Zhou H (2022) Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis. Front Immunol 13:953993. https:\/\/doi.org\/10.3389\/fimmu.2022.953993","journal-title":"Front Immunol"},{"key":"9000_CR20","doi-asserted-by":"publisher","unstructured":"Sneed SL, Reese BB, Laureano AF, Ratnapriya S, Fraschilla I, Jeffrey KL, Coffey GP, Conley PB, RM Anthony (2024) An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin. J Clin Invest 134. https:\/\/doi.org\/10.1172\/jci172980","DOI":"10.1172\/jci172980"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09000-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09000-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09000-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:39:44Z","timestamp":1776242384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09000-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["9000"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09000-9","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare that the study followed the ethical guidelines issued by the Declaration of Helsinki. For this case report, written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"397"}}